Top
Ovarian Cancer - Healing Genes
2856
post-template-default,single,single-post,postid-2856,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2540

Ovarian Cancer

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL) (OVAL)

A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer


Phase 3

DESCRIPTION:

Doctors at 49 research centers are seeking patients with recurrent, platinum-resistant ovarian cancer to participate in a 400-patient study comparing a previously trialed drug, VB-111, against placebo when combined with paclitaxel. VB-111 is a genetic therapy which employs a virus to target the angiogenesis factors in tumor epithelial cells that indicate the tumor is growing new blood flow to feed itself. By infecting and killing those specific cells in the tumor, VB-111 starves the tumor and recruits the patient’s own immune response to further fight the cancer.

A portion of participants will be given VB-11 in combination with paclitaxel (Taxol™), while the remainder will receive a placebo and paclitaxel. You will not know which group you are assigned. If effective, the treatment is expected to improve outcomes for the patients.


PATIENT MUST:

  • Be 18 to 65 years of age
  • Have a histologically confirmed epithelial ovarian cancer and must have platinum-resistant disease
  • Not have any prior radiotherapy to the pelvis or abdomen

THE STUDY INVOLVES:

  1. Prescreening tests to confirm eligibility of the patient to participate.
  2. VB-111 will be administered intravenously every 2 months
  3. Paclitaxel will be administered intravenously every week
  4. Follow up will continue for up to 5 years after the final treatment

LOCATIONS AND CONTACTS:

49 study sites are participating across the US. See the full list, along with contact information, here.

 

SPONSOR INFORMATION:

Vascular Biogenics Ltd. operating as VBL Therapeutics

GOG Foundation, Inc.

 

Or go online:

https://clinicaltrials.gov/show/NCT03398655

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader